A market stall piled with fresh vegetables and fruit

High cholesterol

Also called hyperlipidemia, dyslipidemia, LDL cholesterol, familial hypercholesterolemia, lipoprotein(a), Lp(a), statins

Too much LDL ("bad") cholesterol builds plaque in the arteries. Lowering it prevents heart attacks and strokes, and the 2026 guideline pushes for earlier, more intensive treatment.

Updated 5 sources

Photo: Hillbraith (Public domain)

This entry is a draft and is still being reviewed.

Types

  • High LDL cholesterol — the main driver of artery plaque1,2.
  • Familial hypercholesterolemia (FH) — an inherited form with very high LDL from birth. It affects roughly 1 in 200 to 1 in 500 people, and most don't know they have it4.
  • High lipoprotein(a) — a cholesterol-carrying particle whose level is set mostly by genes5.
  • High triglycerides and low HDL, often alongside obesity, diabetes, or heavy drinking1.

Prevention

  • Lifestyle comes first; if cholesterol stays above goal, the 2026 guideline recommends starting medication earlier than before1.
  • Every 1 mmol/L (about 39 mg/dL) drop in LDL cholesterol lowers the risk of major cardiovascular events by about 22%2.

Risk factors

  • Diets high in saturated and trans fats, excess weight, and inactivity1
  • Family history and genetics, including FH4
  • Type 2 diabetes, chronic kidney disease, and an underactive thyroid1
  • Older age, and menopause1

Diagnostics

  • Lipid panel: total, LDL, HDL, and non-HDL cholesterol plus triglycerides; fasting usually isn't needed1.
  • Lipoprotein(a) measured at least once in adulthood1.
  • PREVENT risk calculator for adults 30 to 79: 10-year risk below 3% is low, 3% to under 5% borderline, 5% to under 10% intermediate, and 10% or more high1.
  • Coronary artery calcium (CAC) scan can help decide on a statin when risk is borderline or intermediate1.
  • Suspect FH with very high LDL (190 mg/dL or higher in adults), especially with early heart disease in close relatives1,4.

Treatments

LDL goals in the 2026 ACC/AHA guideline1:

  • Below 100 mg/dL — borderline or intermediate risk
  • Below 70 mg/dL — high risk
  • Below 55 mg/dL — very high-risk people who already have cardiovascular disease

Statins are the foundation; other drugs are added when goals aren't met1. Adding evolocumab to a statin lowered LDL by 59% and reduced heart attacks and strokes in people with cardiovascular disease3.

Molecular Biomarkers

  • LDL and non-HDL cholesterol1
  • Apolipoprotein B (ApoB) — counts plaque-forming particles; helpful for gauging leftover risk in diabetes, high triglycerides, or existing heart disease once LDL goals are met1
  • Lipoprotein(a) — 125 nmol/L (about 50 mg/dL) or higher raises long-term risk of heart attack and stroke1,5
  • Triglycerides1

Genes

  • FH genes: LDLR (the most common), APOB, and PCSK94.
  • LPA sets lipoprotein(a) levels, which are largely inherited and stay stable for life5.
  • Genetic testing confirms FH and makes it possible to test relatives (cascade testing)4.

Lifestyle

  • Keep a healthy weight, stay active, avoid tobacco, and sleep well1.
  • Lifestyle changes barely move lipoprotein(a), so a high level needs attention to every other risk factor1,5.

Nutrition

  • Swap saturated fats (fatty meat, butter, full-fat dairy) for unsaturated fats (olive oil, nuts, fish).
  • Avoid trans fats.
  • Soluble fiber (oats, beans) and plant sterols lower LDL modestly.
  • For high triglycerides, cut alcohol, sugar, and refined starches.

Medical Interventions

  • Coronary artery calcium scanning to guide prevention1
  • Lipoprotein apheresis, which filters LDL from the blood, for severe FH that doesn't respond to medication

Pharmaceutical Drugs

  • Statins: atorvastatin, rosuvastatin, and others1,2
  • Ezetimibe1
  • Bempedoic acid1
  • PCSK9 antibodies: evolocumab, alirocumab1,3
  • Inclisiran — a twice-yearly injection; whether it prevents heart attacks and strokes is still being studied1
  • Icosapent ethyl for persistently high triglycerides in high-risk people

Sources

  1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia. J Am Coll Cardiol. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016
  2. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5
  3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
  4. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478-3490. doi:10.1093/eurheartj/eht273
  5. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. doi:10.1093/eurheartj/ehac361

This page summarizes published research for education. It isn't medical advice and doesn't replace care from a clinician who knows your history. Never start, stop, or change a medication without talking to your prescriber.